General Biotechnology

In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and d…

Canada plays a significant role in the global advancement of scientific discoveries and their translation into commercial opportunities, but is viewed as not fully realizing its commercial potential. A significant problem has been a lack of sufficient venture capital to take early-stage companies to the next level. Several recent developments may signal the arrival of a more positive venture-funding environment for life sciences and health technology enterprises, including the development of the Canadian government’s C$400 million Venture Capital Action Plan; pharmaceutical companies electing to establish or investing in venture funds and providing strategic support to early-stage ventures, including through the creation of research centres; and recent successful liquidity events for venture investors.

Abstract

The growing share of biopharmaceuticals is paralleled by an increasing interest in biogenerics, as blockbuster biologics are approaching their patent expiries. Companies need to make decisions whether to invest in biosimilars or in biobetters with enhanced properties, the latter enabling favorable differentiation vis-à-vis the original product on the one hand and biosimilars on the other hand. Net present value (NPV) modelling was applied to evaluate the financial attractiveness of two categories of biobetters in comparison to biosimilars, and recommendations are made which options should be preferred depending on a company’s business model.

The FTC is reportedly seeking $1 billion from pharmaceutical companies for the role in paying generic companies not to challenge

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape
Go to paperABSTRACT: Patent analytical da…

For those who missed the live presentation, here is the discussion of the 2014 Scientific American Worldview scorecard, featuring myself,

Join me on Tuesday March 25th at 11am EST for a discussion of global biotechnology. I will be discussing the

2013 and 2014 have been very good for biotechnology public markets. 35 biotechnology companies went public in 2013, and well

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?

Susan Finston’s recent post on redefining protein products has raised some debate on the regulatory status of short peptides. What